William Blair analyst Raju Prasad maintained a Buy rating on Celyad (CYAD) today. The company’s shares closed last Monday at $10.72, close to its 52-week low of $8.10.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 13.8% and a 53.4% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Celyad with a $51.50 average price target, implying a 399.5% upside from current levels. In a report issued on November 6, JonesTrading also reiterated a Buy rating on the stock with a $60.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $28.35 and a one-year low of $8.10. Currently, Celyad has an average volume of 33.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms.
